I really like Moderna (NASDAQ:MRNA). The company’s COVID-19 vaccine has been instrumental in preventing infections, hospitalizations, and (most importantly) deaths. Its messenger RNA (mRNA) platform could be used to develop vaccines and therapies targeting a wide range of diseases. I’m not surprised that Moderna ranked No. 3 on the Axios-Harris annual survey of corporate reputations and was the top healthcare company on the list.
But it’s possible to like a company, yet not be a fan of its stock. Moderna was a great stock to buy in 2020 and even earlier this year. However,....More>>>